Literature DB >> 19702476

Correlates of cervicovaginal human papillomavirus detection in perimenopausal women.

Keri N Althoff1, Proma Paul, Anne E Burke, Raphael Viscidi, Meera Sangaramoorthy, Patti E Gravitt.   

Abstract

OBJECTIVE: The aim of this research was to determine correlates of prevalent cervicovaginal human papillomavirus (HPV) infection in perimenopausal women.
METHODS: A total of 178 women, ages 40-60, were recruited from four clinics in the metropolitan area of Baltimore, Maryland. A self-collected cervicovaginal specimen and questionnaire were completed following enrollment and consent. HPV was detected by L1 consensus polymerase chain reaction (PCR) and genotyped using a prototype line blot assay. Adjusted prevalence ratios (aPR) and 95% confidence intervals (CIs) from Poisson regression models with robust variance identified correlates of prevalent HPV infection.
RESULTS: Prevalence of any HPV genotype at baseline among 172 women with complete data was 20% (6% for high-risk HPV). HPV prevalence was higher among single compared to married women (aPR = 4.3 [95% CI: 2.0, 9.5]), and among women with >or=2 sex partners in the last six months compared to women who reported none (aPR = 4.9 [1.7, 13.9]) after adjustment for confounders. Menopausal stage was also associated with HPV detection, with increased prevalence among perimenopausal compared to premenopausal women (aPR 2.3 [1.1, 5.1]), after adjustment for confounders. Age was moderately correlated with menopausal staging (r = 0.57).
CONCLUSIONS: Our observations suggest the independent associations of sexual behavior and hormones on prevalent HPV in perimenopausal women. Age was not a good surrogate for menopausal stage, as it was only moderately correlated with menopausal stage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702476      PMCID: PMC2825723          DOI: 10.1089/jwh.2008.1223

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  23 in total

1.  Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio.

Authors:  T Behrens; D Taeger; J Wellmann; U Keil
Journal:  Methods Inf Med       Date:  2004       Impact factor: 2.176

2.  Vaginal self sampling versus physician cervical sampling for HPV among younger and older women.

Authors:  T Karwalajtys; M Howard; J W Sellors; J Kaczorowski
Journal:  Sex Transm Infect       Date:  2006-08       Impact factor: 3.519

3.  Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

Authors:  G M Clifford; S Gallus; R Herrero; N Muñoz; P J F Snijders; S Vaccarella; P T H Anh; C Ferreccio; N T Hieu; E Matos; M Molano; R Rajkumar; G Ronco; S de Sanjosé; H R Shin; S Sukvirach; J O Thomas; S Tunsakul; C J L M Meijer; S Franceschi
Journal:  Lancet       Date:  2005 Sep 17-23       Impact factor: 79.321

Review 4.  Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis.

Authors:  Patrick Petignat; Daniel L Faltin; Ilan Bruchim; Martin R Tramèr; Eduardo L Franco; François Coutlée
Journal:  Gynecol Oncol       Date:  2007-02-28       Impact factor: 5.482

5.  Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda.

Authors:  Mahboobeh Safaeian; Mohammed Kiddugavu; Patti E Gravitt; Joseph Ssekasanvu; Dan Murokora; Marc Sklar; David Serwadda; Maria J Wawer; Keerti V Shah; Ron Gray
Journal:  Sex Transm Dis       Date:  2007-07       Impact factor: 2.830

6.  Hormonal changes and biomarkers in late reproductive age, menopausal transition and menopause.

Authors:  G E Hale; H G Burger
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2008-12-01       Impact factor: 5.237

Review 7.  Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis.

Authors:  Silvia de Sanjosé; Mireia Diaz; Xavier Castellsagué; Gary Clifford; Laia Bruni; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Infect Dis       Date:  2007-07       Impact factor: 25.071

Review 8.  The complex role of estrogens in inflammation.

Authors:  Rainer H Straub
Journal:  Endocr Rev       Date:  2007-07-19       Impact factor: 19.871

9.  A comparison of cervical and vaginal human papillomavirus.

Authors:  Philip E Castle; Ana C Rodriguez; Carolina Porras; Rolando Herrero; Mark Schiffman; Paula Gonzalez; Allan Hildesheim; Robert D Burk
Journal:  Sex Transm Dis       Date:  2007-11       Impact factor: 2.830

10.  Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

Authors:  Rolando Herrero; Allan Hildesheim; Ana C Rodríguez; Sholom Wacholder; Concepción Bratti; Diane Solomon; Paula González; Carolina Porras; Silvia Jiménez; Diego Guillen; Jorge Morales; Mario Alfaro; Jean Cyr; Kerrygrace Morrisey; Yenory Estrada; Bernal Cortés; Lidia Ana Morera; Enrique Freer; John Schussler; John Schiller; Douglas Lowy; Mark Schiffman
Journal:  Vaccine       Date:  2008-07-18       Impact factor: 3.641

View more
  22 in total

1.  High prevalence of oncogenic HPV-16 in cervical smears of asymptomatic women of eastern Uttar Pradesh, India: a population-based study.

Authors:  Shikha Srivastava; Sadhana Gupta; Jagat Kumar Roy
Journal:  J Biosci       Date:  2012-03       Impact factor: 1.826

2.  Comparison of normalization methods for measuring immune markers in cervical secretion specimens.

Authors:  Morgan A Marks; Yolanda Eby; Roslyn Howard; Patti E Gravitt
Journal:  J Immunol Methods       Date:  2012-06-04       Impact factor: 2.303

3.  Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women.

Authors:  Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Shu-Kuang Lee; Sandra F O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  Sex Transm Dis       Date:  2012-11       Impact factor: 2.830

4.  Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study.

Authors:  Jing Ye; Xiaodong Cheng; Xiaojing Chen; Feng Ye; Weiguo Lü; Xing Xie
Journal:  Virol J       Date:  2010-03-23       Impact factor: 4.099

5.  Population-based study on the prevalence of and risk factors for human papillomavirus infection in Qujing of Yunnan province, Southwest China.

Authors:  Lu-lu Sun; Qiong Jin; Hui Li; Xian-rong Zhou; Zhi-qin Song; Xue-mei Cheng; Tao Tao; Bing Liang; Lin Xu; Yu-rong Wang; Yan Zhen; Ji-wen He; Keng Shen
Journal:  Virol J       Date:  2012-08-08       Impact factor: 4.099

6.  The potential impact of HPV-16 reactivation on prevalence in older Australians.

Authors:  Igor A Korostil; David G Regan
Journal:  BMC Infect Dis       Date:  2014-06-06       Impact factor: 3.090

7.  Human papillomavirus prevalence and type-distribution among women in Zhejiang Province, Southeast China: a cross-sectional study.

Authors:  Xiao-Xiang Liu; Xing-Li Fan; Yue-Ping Yu; Lei Ji; Jie Yan; Ai-Hua Sun
Journal:  BMC Infect Dis       Date:  2014-12-19       Impact factor: 3.090

8.  Prevalence of HPV infection among 28,457 Chinese women in Yunnan Province, southwest China.

Authors:  Zheng Li; Feng Liu; Si Cheng; Lei Shi; Zhiling Yan; Jie Yang; Li Shi; Yufeng Yao; Yanbing Ma
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

Review 9.  Applying a gender lens on human papillomavirus infection: cervical cancer screening, HPV DNA testing, and HPV vaccination.

Authors:  Ivan Branković; Petra Verdonk; Ineke Klinge
Journal:  Int J Equity Health       Date:  2013-02-08

10.  Human papillomavirus types distribution in organised cervical cancer screening in France.

Authors:  Isabelle Heard; Laura Tondeur; Laurence Arowas; Michael Falguières; Marie-Christine Demazoin; Michel Favre
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.